
Sector
Pharma
Entry Date
2010
Business
Venture Capital
Poxel
Innovative therapeutic solutions for type II diabetes patients
Poxel is a fast-growing biopharmaceutical company that exclusively develops novel drugs treating metabolic conditions and type II diabetes in particular.
Headquartered in Lyon, Poxel was spun off from Merck Serono in 2009 and is a leading global player in the field of metabolic disorders. Its flagship product, Imeglimin, successfully conducted a Phase II(b).